Prenatal Delivery of Enzyme Replacement Therapy to Fetuses Affected by Early-Onset Lysosomal Storage Diseases. [PDF]
Borges B +8 more
europepmc +1 more source
Case Report: A case of surgical and enzyme replacement therapy for type I Gaucher disease complicating femoral shaft pathological fracture. [PDF]
Gao Y +6 more
europepmc +1 more source
Case report of neuronopathic mucopolysaccharidosis type II: Early intracerebroventricular enzyme replacement therapy and hematopoietic cell transplantation with developmental outcomes up to 5 years of age. [PDF]
Ikari A, Hama A, Okuyama T.
europepmc +1 more source
Outcome of enzyme replacement therapy for hematological and visceral manifestations in children with acid sphingomyelinase deficiency: a single center experience in upper Egypt. [PDF]
Youssef MAM, Shaker EH, Saleh NAM.
europepmc +1 more source
Targeted nanoliposomes to improve enzyme replacement therapy of Fabry disease. [PDF]
Tomsen-Melero J +25 more
europepmc +1 more source
Related searches:
Pancreatic enzyme replacement therapy
Current Gastroenterology Reports, 2001Malabsorption due to severe pancreatic exocrine insufficiency is one of the most important late features of chronic pancreatitis. Generally, steatorrhea is more severe and occurs several years prior to malabsorption of other nutrients because synthesis and secretion of lipase are impaired more rapidly, its intraluminal survival is shorter, and the lack
P, Layer, J, Keller, P G, Lankisch
openaire +2 more sources
Enzyme Replacement Therapy for the Sphingolipidoses
1976The greatest progress in the field of inheritable disorders during the past decade was made in the understanding and control of lipid storage diseases. Since original demonstrations in 1965 and 1966 of the metabolic defects in Gaucher’s disease (6,7) Niemann-Pick disease (8), Fabry’s disease (9), and metachromatic leukodystrophy (17), specific enzyme ...
R O, Brady +8 more
openaire +2 more sources
Enzyme-Replacement Therapy in Mucopolysaccharidosis I
New England Journal of Medicine, 2001Mucopolysaccharidosis I is a lysosomal storage disease caused by a deficiency of the enzyme alpha-L-iduronidase. We evaluated the effect of enzyme-replacement therapy with recombinant human alpha-L-iduronidase in patients with this disorder.We treated 10 patients with mucopolysaccharidosis I (age, 5 to 22 years) with recombinant human alpha-L ...
Emil D. Kakkis +16 more
openaire +2 more sources
Fabry disease: enzyme replacement therapy
Journal of the European Academy of Dermatology and Venereology, 2003ABSTRACTFabry disease is a multisystem disorder associated with wide variability in clinical expression. Fabry disease is an X‐linked lysosomal storage disorder caused by a deficiency of α‐galactosidase A. The enzyme defect leads to the systemic accumulation of glycosphingolipids with α‐galactosyl moieties consisting predominantly of ...
M R, Bongiorno, G, Pistone, M, Aricò
openaire +2 more sources

